Sichuan Huiyu Pharmaceutical Irinotecan Hydrochloride Injection Enters Administrative Approval

Medical Network News, March 17 Recently, Sichuan Huiyu Pharmaceutical has entered the administrative examination and approval stage with the imitation of irinotecan hydrochloride injection for production of category 4 products
.
According to data from Menet.
com, in 2019, the sales of terminal irinotecan hydrochloride injection in China's public medical institutions exceeded 1.
8 billion yuan, and Hengrui led the market
.
At present, Sichuan Huiyu Pharmaceutical has approved 6 anti-tumor injections with new classifications for production
.
Source: State Drug Administration official website Irinotecan hydrochloride is a topoisomerase I inhibitor (L-antitumor and immunosuppressant) that inhibits cell growth.
It can specifically inhibit DNA topoisomerase I and is clinically suitable for advanced stages.
Treatment of colorectal cancer
.
According to data from Minai.
com, in 2019, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal irinotecan hydrochloride injection (irinotecan hydrochloride injection, irinote hydrochloride for injection) Kang) sales exceeded 1.
8 billion yuan, a year-on-year increase of 8.
91%
.
Under the influence of the epidemic in the first half of 2020, irinotecan hydrochloride injection still achieved a growth of 2.
31%
.
From the perspective of the competitive landscape of manufacturers, Hengrui Pharmaceuticals has an exclusive market share of over 60%, and the original research manufacturer Pfizer ranked third with a market share of 15.
2%
.
Consistency evaluation of irinotecan hydrochloride injection (including new classifications for production) Source: Meinenet MED2.
0 Chinese drug review database Currently, Qilu, Hengrui and other companies submit supplementary applications for consistency evaluation of irinotecan hydrochloride injection , Qilu’s products have been successfully reviewed and are the first in China; Fresenius Kabi, Fosun, Huiyu and other companies have applied for new classifications for production.
Among them, Fosun and Huiyu’s products have entered the stage of administrative approval and are sprinting for the first time.
2 reviews
.
Sichuan Huiyu Pharmaceutical’s approved new classification report product source: Meinnet.
com MED2.
0 Chinese Drug Evaluation Database Anti-tumor injection is the main direction of Sichuan Huiyu Pharmaceutical.
Data from Meinenet shows that the company currently has 6 new classifications.
The reported products have been approved for production and deemed to have been reviewed, and the 6 new products are all anti-tumor injections
.
Source: Minainet database, official website of the State Food and Drug Administration.
Note: Statistics are as of March 16, if any omissions, please correct me!